Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood
Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood
复制标题
DOI：
10.1073/pnas.1701517114
复制
发表时间：
2017-09-19
影响因子：
11.1
通讯作者：
Martin, Francis L.
中科院分区：
文献类型：
--
作者：
Paraskevaidi, Maria;Morais, Camilo L. M.;Martin, Francis L.
世界人口的逐渐老龄化使得神经退行性疾病的发病率不可避免地上升。迫切需要一种准确、但同时又便宜和微创的诊断测试，不仅要确认疾病的存在，而且要区分不同类型的痴呆症，以提供适当的管理和治疗。在这项研究中，衰减全反射FTIR （ATR-FTIR）光谱结合化学计量技术分析了我们队列的血浆样本。血液样本很容易通过传统的静脉穿刺收集，允许对同一个人进行重复测量，以监测他们多年来的进展或评估任何测试药物。我们纳入了549名个体：347名患有各种神经退行性疾病的个体和202名年龄匹配的健康个体。阿尔茨海默病（AD, n = 164）的检测灵敏度和特异性均为70%，纳入载脂蛋白epsilon 4基因型（APOE epsilon 4）信息后，当个体携带一个或两个epsilon 4等位基因时，检测灵敏度和特异性分别为86%和72%，当个体不携带epsilon 4等位基因时，检测灵敏度和特异性分别为77%。早期AD病例（n = 14）的识别灵敏度为80%，特异性为74%。将AD与伴路易体痴呆（DLB; n = 34）分离，具有90%的敏感性和特异性。其他神经退行性疾病，如额颞叶痴呆（FTD, n = 30）、帕金森病（PD, n = 32）和进行性核上性麻痹（PSP, n = 31），也被纳入我们的队列进行诊断。我们的方法允许快速和稳健的诊断神经变性和区分不同的痴呆症。
The progressive aging of the world's population makes a higher prevalence of neurodegenerative diseases inevitable. The necessity for an accurate, but at the same time, inexpensive and minimally invasive, diagnostic test is urgently required, not only to confirm the presence of the disease but also to discriminate between different types of dementia to provide the appropriate management and treatment. In this study, attenuated total reflection FTIR (ATR-FTIR) spectroscopy combined with chemometric techniques were used to analyze blood plasma samples from our cohort. Blood samples are easily collected by conventional venepuncture, permitting repeated measurements from the same individuals to monitor their progression throughout the years or evaluate any tested drugs. We included 549 individuals: 347 with various neurodegenerative diseases and 202 age-matched healthy individuals. Alzheimer's disease (AD; n = 164) was identified with 70% sensitivity and specificity, which after the incorporation of apolipoprotein epsilon 4 genotype (APOE epsilon 4) information, increased to 86% when individuals carried one or two alleles of epsilon 4, and to 72% sensitivity and 77% specificity when individuals did not carry epsilon 4 alleles. Early AD cases (n = 14) were identified with 80% sensitivity and 74% specificity. Segregation of AD from dementia with Lewy bodies (DLB; n = 34) was achieved with 90% sensitivity and specificity. Other neurodegenerative diseases, such as frontotemporal dementia (FTD; n = 30), Parkinson's disease (PD; n = 32), and progressive supranuclear palsy (PSP; n = 31), were included in our cohort for diagnostic purposes. Our method allows for both rapid and robust diagnosis of neurodegeneration and segregation between different dementias.